Using prospective samples obtained 8 years (median) before multiple myeloma diagnosis, Hofmann and colleagues (12) did not observe associations between multiple myeloma risk and serum levels of FGF-2, VEGF, and TGF-α. This evidence concerns the gene FGF2 and AL amyloidosis.